Emerging studies suggest Retatru tide , a dual agonist targeting both incretin and another hormone, may offer a significant advancement for obesity loss . Preliminary patient investigations have shown impressive reductions in visceral tissue, potentially surpassing current body composition medications . Nevertheless , additional assessment is neces